Cargando…
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
BACKGROUND: Incretin glucagon-like peptide-1 (GLP-1) is a hormone released from cells in the gastrointestinal tract (GI), leading to glucose-dependent insulin release from the pancreas. It also suppresses postprandial hyperglycemia, glucagon secretion and slows gastric emptying. Exenatide (EXE), a f...
Autores principales: | Robles, Gisela I, Singh-Franco, Devada |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769236/ https://www.ncbi.nlm.nih.gov/pubmed/19920937 |
Ejemplares similares
-
Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
por: Odegard, Peggy Soule, et al.
Publicado: (2009) -
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
por: Raman, Vandana S., et al.
Publicado: (2010) -
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022) -
Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)